Early research (Phase 1)Ended earlyNCT02387125
What this trial is testing
Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Who this might be right for
SarcomaMelanomaNon-small Cell Lung Cancer+1 more
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 79